Arjun Balar, Robert Dreicer, Ashish Kamat

Arjun Balar, MD

Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center NYU Langone Health
New York, New York

Dr. Balar is an Assistant Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center in New York, New York.

Dr. Balar received his Medical Degree from the University of South Florida-Morsani College of Medicine in Tampa, Florida, as a member of the Alpha-Omega-Alpha Honor Medical Society. He completed his Internal Medicine residency at New York-Presbyterian/Weill Cornell Medical Center in New York, New York, and went on to complete a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York, New York, where his research efforts focused entirely on novel therapies in muscle-invasive and metastatic bladder cancer.

Dr. Balar has focused primarily on cisplatin-ineligible patients with the goal of identifying better tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer, with a particular focus on novel immunotherapies and combinations.

Back to top

Robert Dreicer, MD, MS, MACP, FASCO

Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Section Head, Medical Oncology
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Cancer Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine in Charlottesville, Virginia. He previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr. Dreicer is Board Certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies, and the design and conduct of clinical trials in urologic oncology.

Dr. Dreicer received his Bachelor of Science at Colorado State University and his Master of Science at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his Medical Degree from the University of Texas Medical School in Houston, Texas. He completed an Internal Medicine residency at Indiana University in Indianapolis, Indiana, followed by a Medical Oncology Fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology, and has served as Principal Investigator in a large number of studies in genitourinary neoplasms. He is Co-Chair of National Cancer Institute Genitourinary Cancers Steering Committee and a member of the editorial board of New England Journal of Medicine’s Journal Watch Hematology and Oncology. In October 2016, he was awarded Mastership in the American College of Physicians.

Back to top

Ashish Kamat, MD, MBBS, FACS (Activity Chair)

Professor, Department of Urology
Wayne B. Duddlesten Professor of Cancer Research
Associate Cancer Center Director, RFHNH, Mumbai
University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Kamat is a Professor of Urology and Wayne B. Duddlesten Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. He is also the Associate Head of the Cancer Center, Reliance Foundation Hospital in Mumbai, served as the Director of the MD Anderson Urologic Oncology Fellowship Program from 2005-2016 and is a 2008 graduate of the American Urological Association (AUA) Leadership Program.

Dr. Kamat is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ-sparing and minimally invasive techniques. He maintains an active research portfolio in this area with a focus on developing novel therapies, and identifying predictors of response to therapy (eg, intravesical immunotherapy), as a first step toward personalized cancer therapeutics. He has initiated, led, and been active in several large studies, including multinational trials in bladder cancer with findings published in high-impact journals. Dr. Kamat is a Co-Principal Investigator on the MD Anderson GU SPORE (Bladder).

Dr. Kamat is an exceptional educator, and as Program Director, grew the Urologic Oncology Fellowship Program into the premier program in the U.S. He has been nominated twice for the Robert M. Chamberlain Distinguished Mentor Award.

Dr. Kamat has authored numerous editorials, book chapters, and more than 225 publications in peer-reviewed journals, and serves on the editorial board of high-ranked journals. He is listed in "Who’s Who in Medicine’" and "Best Doctors in America" and has won the "Compassionate Doctor Award" from patient groups. He is recognized internationally for his efforts and has been invited as a visiting professor to several universities in the U.S. and elsewhere to deliver invited plenary sessions nationally (American Urological Association [AUA]) and internationally (e.g., European Association of Urology, Japanese Urological Association, Société Internationale d’Urologie, Urological Society of India); to chair related committees (eg, Society of Immunotherapy for Cancer); and as an AUA International Faculty. He is also a member of the AUA Guidelines Panel for Bladder Cancer.

Dr. Kamat is President of the International Bladder Cancer Group and, Co-President of the International Bladder Cancer Network; he Chaired the Bladder Cancer Think Tank and actively participates in various global urologic efforts (eg, setting up cancer centers overseas), serves on the boards of regional and national societies for Urology (South Central Section of the AUA, Texas Urologic Society) and Urologic Oncology (Society of Urologic Oncology Clinical Trials Consortium), and also in patient advocacy groups (MD Anderson Bladder Support Group, Bladder Cancer Advocacy Network, etc.).

Back to top